Three Peptides, Three Routes Into Brain Adaptability

The short version

This page lines up semax, selank and DSIP by mechanism, main research question, evidence maturity and central caution. All three appear in discussions of brain adaptability, but they approach that subject from different directions. Semax has the clearest neurotrophin story, with region-specific BDNF and NGF changes in rodent brain ^[3][4]. Selank is studied mainly through GABA, the brain's primary inhibitory signaling system, with a separate hippocampal BDNF finding ^[8][11]. DSIP is associated with sleep and stress-hormone research, yet its receptor and broader mechanism remain unresolved ^[14].

Those differences matter more than the shared label "nootropic peptide." Animal models dominate the record, the human evidence varies sharply, and DSIP's native sleep-promoting case is especially weak. The matrix below is a reading aid, not a ranking of products or a claim that findings transfer between compounds. None of the three is FDA-approved for human use, and this page provides neither medical advice nor human dosing guidance.

The comparison matrix

Mechanism

Semax and selank both descend from the same design template — a short natural-hormone fragment stabilized with an added Pro-Gly-Pro tail — but they act on different systems. Semax's best-documented action is a fast, region-specific rise in the neurotrophins BDNF and NGF ^[3][4], plus an enkephalinase-inhibiting action shared with selank ^[7]. Selank's best-documented action is positive allosteric modulation of GABA receptors, the brain's primary inhibitory system, an effect distinct from benzodiazepines in its subtype selectivity ^[8], layered with its own separate, smaller BDNF signal in rat hippocampus ^[11] and a documented immunomodulatory profile inherited from its tuftsin backbone ^[12]. DSIP stands apart from both: despite more than forty years of research, it has no identified receptor, gene or precursor protein, and the mechanisms proposed for it — a saturable blood-brain-barrier transporter, a dopaminergic relay, a possible opioid-system interaction — remain partial and unconfirmed ^[14].

Most-studied application

Semax's densest research clusters around neuroprotection and recovery from brain and spinal-cord injury — stroke models, spinal-cord injury, and the cognitive/memory performance that follows from its neurotrophin action ^[1][2][5]. Selank's research clusters around anxiety reduction, both in animal stress models and in a small set of Russian clinical patients with anxiety-asthenic disorders ^[8][9][12]. DSIP's research is the most scattered of the three: older human pilot studies of sleep and HPA-axis modulation ^[16][17], a single-lineage rodent longevity study ^[15], and a modern 2024 fusion-peptide insomnia-model study that represents the field's newest and most methodologically rigorous entry ^[13].

Evidence maturity

This is where the three genuinely separate. Semax has the largest evidence base on this desk — seven cited studies spanning gene expression, protein-level neurotrophin data, two separate injury models, and pharmacokinetics — though it remains, like the other two, a predominantly rodent and Russian-language literature without independent Western clinical trials ^[1]–^[7]. Selank's evidence base is smaller but includes a direct human patient study of immunomodulation, a genuine point of strength relative to the other two ^[12]. DSIP's evidence base is the thinnest and most contested: its own most-cited review calls the core sleep-promotion hypothesis "extremely poorly documented and still weak," no receptor has ever been confirmed, and the strongest recent evidence (the 2024 fusion-peptide study) concerns an engineered analog rather than the native peptide ^[14][13].

Regulatory status

Semax and selank share a regulatory pattern: both are registered prescription pharmaceuticals in Russia (and, for semax, also historically in Ukraine) for specific clinical indications, and both are sold everywhere else, where sold at all, strictly as unscheduled research chemicals with no regulator verifying identity, purity or sterility. DSIP has never achieved that regulatory status anywhere — its international nonproprietary name, Emideltide, has never been attached to an approved drug product by any regulator, and an unverified online claim of a 2026 FDA compounding docket for Emideltide could not be substantiated and should not be repeated. None of the three is approved by the FDA or EMA for any human use.

Key caution

Each compound carries a defining caveat that a reader should weigh before drawing any conclusion. For semax, it is that the neurotrophin and gene-expression effects documented in the literature are genuinely powerful — not trivial tweaks to brain signaling — and their consequences from repeated, long-term use in a healthy human brain have simply not been studied ^[3][4][2]. For selank, it is the breadth of systems it touches at once — GABAergic, opioid, monoaminergic and immune — each representing a largely unstudied interaction surface with common medications ^[9][12]. For DSIP, it is the combination of an unidentified mechanism, a non-monotonic dose-response, and a community record in which a large share of users report no effect at all — a pattern that should temper expectations more than either of the other two compounds ^[14]. Read together, the pattern across all three is the same one this desk returns to throughout: real, cited biological signals exist, but the human evidence supporting any of them is thinner and older than the enthusiasm around them online.